JP2022552152A5 - - Google Patents

Info

Publication number
JP2022552152A5
JP2022552152A5 JP2022520447A JP2022520447A JP2022552152A5 JP 2022552152 A5 JP2022552152 A5 JP 2022552152A5 JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022552152 A5 JP2022552152 A5 JP 2022552152A5
Authority
JP
Japan
Prior art keywords
approximately
seq
amino acid
histidine
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520447A
Other languages
English (en)
Japanese (ja)
Other versions
JP7805289B2 (ja
JP2022552152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054036 external-priority patent/WO2021067775A1/en
Publication of JP2022552152A publication Critical patent/JP2022552152A/ja
Publication of JP2022552152A5 publication Critical patent/JP2022552152A5/ja
Priority to JP2025010928A priority Critical patent/JP2025061811A/ja
Application granted granted Critical
Publication of JP7805289B2 publication Critical patent/JP7805289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520447A 2019-10-02 2020-10-02 抗コネキシン抗体製剤 Active JP7805289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025010928A JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909267P 2019-10-02 2019-10-02
US62/909,267 2019-10-02
PCT/US2020/054036 WO2021067775A1 (en) 2019-10-02 2020-10-02 Anto-connexin antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025010928A Division JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Publications (3)

Publication Number Publication Date
JP2022552152A JP2022552152A (ja) 2022-12-15
JP2022552152A5 true JP2022552152A5 (cg-RX-API-DMAC7.html) 2023-10-10
JP7805289B2 JP7805289B2 (ja) 2026-01-23

Family

ID=75273959

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520447A Active JP7805289B2 (ja) 2019-10-02 2020-10-02 抗コネキシン抗体製剤
JP2025010928A Pending JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025010928A Pending JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Country Status (8)

Country Link
US (2) US12358981B2 (cg-RX-API-DMAC7.html)
EP (1) EP4037703A4 (cg-RX-API-DMAC7.html)
JP (2) JP7805289B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220113355A (cg-RX-API-DMAC7.html)
CN (1) CN114786719A (cg-RX-API-DMAC7.html)
AU (1) AU2020358101A1 (cg-RX-API-DMAC7.html)
CA (1) CA3156812A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021067775A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
CN115825201B (zh) * 2022-07-28 2024-10-25 苏州凯劳生物科技有限公司 一种使用毛细管电泳仪电离还原蛋白二硫键并确定其自由巯基比例的方法
WO2025199516A1 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions and methods for preserving or increasing lean muscle mass

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
WO2005116236A2 (en) * 2004-05-14 2005-12-08 The Regents Of The University Of California Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
RU2408728C1 (ru) 2009-07-28 2011-01-10 Федеральное государственное учреждение "Государственный Научный Центр Социальной и Судебной Психиатрии им. В.П. Сербского" (ФГУ "ГНЦССП Росздрава") Способ получения иммуногенного рекомбинантного экстраклеточного фрагмента коннексина-43
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
RU2457862C1 (ru) 2011-07-07 2012-08-10 Федеральное государственное учреждение "Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского" Министерства здравоохранения и социального развития Российской Федерации Способ лечения низкодифференцированных глиом
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
CA2944330A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
US11427639B2 (en) * 2018-04-02 2022-08-30 Richter Gedeon Nyrt. Antibody-containing aqueous formulation and use thereof

Similar Documents

Publication Publication Date Title
JP2023537316A5 (cg-RX-API-DMAC7.html)
TWI883117B (zh) Tubulysin衍生物與細胞結合分子偶聯物的製劑配方
KR102603344B1 (ko) 분지형 링커를 갖는 튜불리신 유사체의 접합체
JP2021512881A5 (cg-RX-API-DMAC7.html)
US11279924B2 (en) Conditionally active polypeptides and methods of generating them
EP2099489B1 (en) Compositions and methods for treating a neoplasm
ES3057518T3 (en) Combination hbv therapy
WO2020155017A1 (en) A conjugate of an amanita toxin with branched linkers
TWI853146B (zh) 細胞結合分子與細胞毒性劑偶聯物
JP2020509031A5 (cg-RX-API-DMAC7.html)
KR20180064534A (ko) 조건부 활성 폴리펩티드
RU2020112302A (ru) Соединения для уменьшения вязкости биологических композиций
CA3016172A1 (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
JP2024506940A5 (cg-RX-API-DMAC7.html)
TW202003046A (zh) 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
FR2995214A1 (fr) Solution a viscosite reduite de proteine a concentration elevee
JP2021520393A5 (cg-RX-API-DMAC7.html)
EA200501131A1 (ru) Парентеральные композиции пептидов для лечения системной красной волчанки
CN116390943A (zh) 工程化乙型肝炎病毒中和抗体和其用途
KR20240134971A (ko) 나노바디-약물 부가물 및 그의 용도
JP2022519796A5 (cg-RX-API-DMAC7.html)
AR130041A1 (es) Formulaciones de anticuerpos anti-tl1a
JPWO2023008337A5 (cg-RX-API-DMAC7.html)
US20120315290A1 (en) Inhibitors of ll-37 mediated immune reactivity to self nucleic acids
US20110033448A1 (en) Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids